chevron_leftBack
As of 24 April 2025, SanBio Company Ltd. has a market cap of $959.24M USD, ranking #8399 globally and #695 in Japan. It ranks #812 in the Healthcare sector, and #195 in the Biotechnology industry.
Key Stats
Market Cap
$959.24MUSD
136.68B JPY
Enterprise Value
$937.44MUSD
134.16B JPY
EBITDA (TTM)
-$24.5MUSD
-3.51B JPY
Net Income (TTM)
-$20.23MUSD
-2.88B JPY
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Keita Mori
open_in_new
Employees
29
Founded
2001
Website
sanbio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -9.1% | -14% | 42% | 177% | 88% | 363% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
4592
サンバイオ株式会社
ISIN: JP3336750009
Shares Out.:
Shares Outstanding:
72.015M1
Shares Float:
52.019M2
|
1.9K JPY | |
|
SNBIF
サンバイオ株式会社
ISIN: JP3336750009
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
11.32 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About SanBio Company Ltd.
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
